Card-brand restrictions on peptide merchants are creating serious consequences throughout the payments industry. Learn how potential six-figure fines against acquiring banks and processors can lead to frozen funds, sudden account closures, and fewer processing options for peptide businesses.

As card brands pressure processors to decline or cancel peptide merchant accounts, 2nd Amendment Processing continues helping eligible businesses explore ACH and cryptocurrency payment options.

Eli Lilly’s tirzepatide patent should not become a blanket ban on peptide processing. We examine Visa’s penalties, corporate pressure, and the growing threat of financial deplatforming.

The FDA's July 2026 review of seven peptides could have far-reaching implications beyond healthcare. As regulators evaluate potential changes to compounding eligibility, payment processors, banks, and merchants are watching closely. Learn how increased regulatory clarity may affect merchant account approvals, underwriting standards, banking relationships, and payment processing opportunities for businesses operating in the peptide industry.

Have stablecoins replaced XRP? Not quite. While stablecoins are transforming digital payments with price stability and faster settlements, XRP continues to play a unique role in cross-border liquidity and currency exchange. Learn the differences, why both technologies matter, and what their growing adoption means for businesses looking to stay ahead in the future of payment processing.

Reliable payment processing is critical for peptide businesses. Learn how 2nd Amendment Processing helps peptide merchants overcome industry challenges with secure, scalable payment solutions. #ProcessWithPurpose